Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17804 | 0.98 | IDO1 (0.57) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL29377714 | 0.98 | IDO1 (0.57) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL11031727 | 0.95 | IDO1 (0.55) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL20913236 | 0.84 | TAAR1 (0.64) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL1279269 | 0.84 | TAAR1 (0.64) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL29447946 | 0.84 | TAAR1 (0.64) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL18725306 | 0.83 | ABCB1 (0.48) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL29783095 | 0.81 | HTR2A (0.48) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL489913 | 0.81 | HTR2A (0.48) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL28854332 | 0.81 | HTR7 (0.49) | IDO1TAAR1CHRM2CHRM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184703-A | Synthesis method of alpha-substituted chiral phosphonate compound | 中国人民解放军军事科学院防化研究院 | 2024-06-14 | — | — | CN | disclosed |
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | IDO1 323/4885TAAR1 18/4885CHRM2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.